{"schema_version":"secwatch.filing_event.v1","accession":"0001326110-25-000044","form_type":"8-K","ticker":"IBRX","cik":"0001326110","company_name":"ImmunityBio, Inc.","filed_at":"2025-04-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:47.936213+00:00","generated_at":"2026-05-23T14:19:16.812624+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"ImmunityBio Q1 net product revenue ~$16.5M (+129% QoQ); submits sBLA for NMIBC papillary disease","bullets":["Q1 2025 net product revenue ~$16.5M (+129% QoQ from $7.2M in Q4 2024).","Unit sales volume in Q1 2025 grew 150% QoQ exceeding FY2024 total; March up 69% MoM.","Submitted sBLA to FDA for ANKTIVA+BCG in BCG-unresponsive NMIBC papillary disease; 93% cystectomy avoidance at 20.7 months.","Submitted Expanded Access Protocol (EAP) for ANKTIVA to treat lymphopenia after RMAT designation in Q1."],"urls":{"canonical":"https://secwatch.observer/filing/0001326110-25-000044","json":"https://secwatch.observer/filing/0001326110-25-000044.json","markdown":"https://secwatch.observer/filing/0001326110-25-000044.md","text":"https://secwatch.observer/filing/0001326110-25-000044.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000044/0001326110-25-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1326110/000132611025000044/ibrx-20250415.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T14:19:16.812624+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}